EcoDrugPlus

Proteasome Subunit Beta Type-8-Like

Ensembl ID : ENSSTUG00000021968
Gene Symbol: LOC115175922
3 Cross references
213 Possible Orthologues:

Proteasome Subunit Beta Type-8-Like

Ensembl ID : ENSSTUG00000032797
Gene Symbol: LOC115173547
3 Cross references
212 Possible Orthologues:

Proteasome Subunit Beta Type-9

Ensembl ID : ENSSTUG00000032944
Gene Symbol: LOC115173550
3 Cross references
200 Possible Orthologues:

Proteasome Subunit Beta Type-9

Ensembl ID : ENSSTUG00000021885
Gene Symbol: LOC115175915
3 Cross references
200 Possible Orthologues:

Protein Arginine N-Methyltransferase 5-Like

Ensembl ID : ENSSTUG00000009454
Gene Symbol: LOC115157327
3 Cross references
192 Possible Orthologues:

Protein Arginine N-Methyltransferase 5-Like

Ensembl ID : ENSSTUG00000008225
Gene Symbol: LOC115169480
3 Cross references
192 Possible Orthologues:

Protein Farnesyltransferase Subunit Beta-Like

Ensembl ID : ENSSTUG00000012964
Gene Symbol: LOC115155577
3 Cross references
201 Possible Orthologues:

Protein Farnesyltransferase/geranylgeranyltransferase Type-1 Subunit Alpha-Like

Ensembl ID : ENSSTUG00000021675
Gene Symbol: LOC115170191
3 Cross references
215 Possible Orthologues:

Protein Farnesyltransferase/geranylgeranyltransferase Type-1 Subunit Alpha-Like

Ensembl ID : ENSSTUG00000004574
Gene Symbol: LOC115205086
3 Cross references
215 Possible Orthologues:

Protein Kinase C Alpha

Ensembl ID : ENSSTUG00000032429
Gene Symbol: PRKCA
3 Cross references
207 Possible Orthologues:

Protein Kinase C Alpha Type-Like

Ensembl ID : ENSSTUG00000031743
Gene Symbol: LOC115177626
3 Cross references
207 Possible Orthologues:

Protein Kinase C Beta

Ensembl ID : ENSSTUG00000021865
Gene Symbol: PRKCB
3 Cross references
82 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).